Swedish bank Handelsbanken has lowered its share price target for Novo Nordisk from DKK 745 (USD 113.5) to DKK 650 (USD 99), while the bank's recommendation remains on "hold," Handelsbanken reports in an analysis.
The change is due to some reservations about Novo Nordisk's 2022 guidance, which will be publicized in the company's financial report for 2021 on February 2. Expectations therein might be on the lower side, as December brought news of supply issues from a subsupplier, which have meant that Novo Nordisk will only be able to meet demand for the the lowest initial doses of weight loss treatment Wegovy to a limited extent in the first half of 2022.
More from MedWatch
In 2015, Genmab partnered with relatively unknown biotech firm Biontech. Reflecting on how far Genmab has come since, CEO Jan van de Winkel is still confident that partnerships, rather than acquisitions, are the way forward. If it had acquired Biontech at the time, the CEO speculates Genmab may have put a stop to other activities – including the Covid-19 vaccine efforts that went on to save millions of lives. This and fairness are worth remembering as biotech firms are increasingly strapped for cash, van de Winkel reflects.